Bowen Raffick A R, Adcock Dorothy M
Department of Pathology, Rm H1401J, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305-5627, United States.
Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, United States.
Clin Biochem. 2016 Dec;49(18):1321-1330. doi: 10.1016/j.clinbiochem.2016.10.004. Epub 2016 Oct 17.
Blood collection tubes (BCTs) are an often under-recognized variable in the preanalytical phase of clinical laboratory testing. Unfortunately, even the best-designed and manufactured BCTs may not work well in all clinical settings. Clinical laboratories, in collaboration with healthcare providers, should carefully evaluate BCTs prior to putting them into clinical use to determine their limitations and ensure that patients are not placed at risk because of inaccuracies due to poor tube performance. Selection of the best BCTs can be achieved through comparing advertising materials, reviewing the literature, observing the device at a scientific meeting, receiving a demonstration, evaluating the device under simulated conditions, or testing the device with patient samples. Although many publications have discussed method validations, few detail how to perform experiments for tube verification and validation. This article highlights the most common and impactful variables related to BCTs and discusses the validation studies that a typical clinical laboratory should perform when selecting BCTs. We also present a brief review of how in vitro diagnostic devices, particularly BCTs, are regulated in the United States, the European Union, and Canada. The verification and validation of BCTs will help to avoid the economic and human costs associated with incorrect test results, including poor patient care, unnecessary testing, and delays in test results. We urge laboratorians, tube manufacturers, diagnostic companies, and other researchers to take all the necessary steps to protect against the adverse effects of BCT components and their additives on clinical assays.
采血管(BCTs)是临床实验室检测分析前阶段一个常常未得到充分认识的变量。不幸的是,即使是设计和制造得最好的采血管在所有临床环境中也可能无法良好发挥作用。临床实验室应与医疗服务提供者合作,在将采血管投入临床使用前仔细评估,以确定其局限性,并确保患者不会因采血管性能不佳导致的不准确结果而面临风险。通过比较广告材料、查阅文献、在科学会议上观察设备、接受演示、在模拟条件下评估设备或使用患者样本测试设备,可以选出最佳采血管。尽管许多出版物讨论了方法验证,但很少详细说明如何进行采血管验证和确认实验。本文重点介绍了与采血管相关的最常见且影响较大的变量,并讨论了典型临床实验室在选择采血管时应进行的验证研究。我们还简要回顾了美国、欧盟和加拿大对体外诊断设备,特别是采血管的监管情况。采血管的验证和确认将有助于避免与错误检测结果相关的经济和人力成本,包括患者护理不佳、不必要的检测以及检测结果延迟。我们敦促检验人员、采血管制造商、诊断公司和其他研究人员采取一切必要措施,防止采血管组件及其添加剂对临床检测产生不利影响。